UK R&D tax changes: unlocking cashflow for life sciences businesses
ArticleDiscover how R&D tax relief can deliver non‑dilutive funding for life sciences businesses and ways to maximise value given recent changes to the UK R&D regime.

In Autumn Budget 2024, the Government announced changes to BPR and APR to be introduced from 6 April 2026. This included the introduction of a new allowance to which 100% relief will apply, with any remaining qualifying property benefitting from a lower 50% relief. On 23 December 2025 the Government announced its intention to increase the allowance from £1 million to £2.5 million per individual. For further information please see our previous insights which can be found here.
Following a consultation period, HMRC published draft legislation and explanatory notes on 21 July 2025 which confirm that the changes will come in largely as expected with a few amendments, the more notable being:
HMRC ran a consultation on the draft legislation which has now ended and we are not expecting any further amendments to the draft legislation.
With just a few months until the proposed changes are due to apply, there is a limited opportunity to review positions and implement any changes. The decisions to be made can be difficult, impacting both business and family life, so delaying matters not only risks challenges with the availability of advisers, but adds unnecessary pressure to business owners to make critical decisions too quickly.
If you are impacted by these rules but have not yet taken any action to develop a succession strategy to mitigate risk, please do get in touch with our experts.
Discover how R&D tax relief can deliver non‑dilutive funding for life sciences businesses and ways to maximise value given recent changes to the UK R&D regime.
UK employers may be facing a growing tax exposure on visa‑related costs they are required to pay.
Explore how recent changes to Business Property Relief (BPR) and Inheritance Tax could impact business owners and the businesses they control.